TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PTSD Coach App Evaluation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Experienced or witnessed an extremely traumatic event that involved actual or threatened death or serious injury to you or someone else. Event must have occurred more than 1 month ago.~2. Significant PTSD symptoms. Total PTSD Checklist Score ≥ 35.~3. Have a smartphone or smart device that can download apps (iPhone, iPod touch, iPad, or android phone or tablet).~4. English is the primary language.~5. Available for the next 6 months to participate in the study and use smart device.~Exclusion Criteria:~1. Unable to give informed consent.~2. Is currently receiving mental health treatment.~3. Currently participating in other PTSD-related research studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTSD Coach (Type: EXPERIMENTAL): Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
- Waitlist Control (Type: ACTIVE_COMPARATOR): Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Helping Empower Liver and Kidney Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must read and understand English AND~* Must have Hepatitis C (any genotype) and Chronic Kidney Disease (any stage)~Exclusion Criteria:~* Developed jaundice, ascites, variceal hemorrhage, or hepatic encephalopathy also known as Decompensated cirrhosis; or~* Currently has or had liver cancer (Hepatocellular carcinoma); or~* Received a liver transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decision Aid (Type: EXPERIMENTAL): A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic Gait Index in Hemiplegic Cerebral Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of spastic unilateral cerebral palsy~* Age between 4 - 16~* Able to stand and walk without any orthosis or special equipment~* Volunteer to study~Exclusion Criteria:~* Being unable to walk~* Having cognitive disorder~* History of orthopedic surgery or any intervention for spasticity within the previous 12 months~* Uncontrolled epilepsy~* Visual conditions that prevent full participation to assessments~* Lower extremity contracture that may affect assessments

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Cerebral Palsy Group (Type: None): 16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
- Healthy Control Group (Type: None): 16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* well document symptoms of rhinitis during birch pollen season~* positive nasal provocation test to birch~* negative results of skin prick tests to inhalant allergen including: D. pteronyssius, D. farinae, grass pollen, birch, hazel, alder Alternaria, and cat.~* negative results of serum total and allergen specific IgE against mentioned allergens.~Exclusion Criteria:~* diagnosis of bronchial asthma, non-allergic rhinitis (especially senile or vasomotor rhinitis) and severe non-stable diseases. All subjects were required to abstain from anti-allergy drugs and glucocorticoid nasal drops for at least 6 weeks prior to the start of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Purethal Birch immunotherapy (Type: ACTIVE_COMPARATOR): Purethat Birch intervention and symptomatic treatment for 24 months
- placebo and symptomatic treatment (Type: PLACEBO_COMPARATOR): placebo intervention and symtomatic treatment during 24 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneous Ig NextGen 16% in PID Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion Criteria:~  * Males or females 3 years of age or greater and at least 13 kg at enrolment.~ * PID patients receiving Ig replacement therapy, with a diagnosis of X-linked agammaglobulinemia (XLA) or Common Variable immunodeficiency (CVID) with severe hypogammaglobulinemia.~ * Patients who have received a consistent dose of Intragam®P at 3-, 4-, 5- or 6-weekly intervals, within the range of 0.2 - 0.6 g/kg body weight, for at least six months prior to the Screening visit.~ * Patients must have maintained IgG trough serum level of ≥ 5 g/L during the six months prior to Visit 0, with at least two trough levels to have been documented during this period.~ * Patients and/or their legally acceptable representative/guardian must give written informed consent to participate in the study and must understand the nature of the study and must be willing to comply with all protocol requirements~Exclusion Criteria:~* • Patients newly diagnosed with PID within six months of the Screening visit.~  * Patients with known or suspected severe hypersensitivity or previous evidence of severe side effects to immunoglobulin therapy or other blood products~ * Patients with known selective IgA deficiency or antibodies to IgA~ * Patients receiving immunosuppressive treatment other than topical and/or inhaled steroids and low dose oral steroids.~ * Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Females who are of child bearing potential must have a negative pregnancy test at screening.~ * Patients with protein-losing enteropathies, and kidney diseases with substantial proteinuria~ * Patients with malignancies of lymphoid cells such as chronic lymphocytic leukaemia, Non-Hodgkin's lymphoma and immunodeficiency with thymoma.~ * Patients who have within 30 days priors to the study screening visit, participated in a clinical study or used an investigational compound (eg: a new chemical entity not registered for clinical use).~ * Patients with any of the following abnormal lab results:~    * Serum creatinine \>1.5 x Upper limit of Normal (ULN).~   * Serum ALT \& AST \> 2.5 x ULN.~   * Albumin \< 25 g/L~ * Patients who are suffering from an acute or chronic medical condition, other than PID, which may, in the opinion of the Investigator, affect the conduct of the trial.~ * Patients who are not willing or are unable to comply with protocol.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ig NextGen 16% (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Duloxetine in Elderly Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You must be able to visit the doctor's office for clinic visits, tests, and procedures.~* You must have been diagnosed with major depression, and have had at least one other episode in the past.~Exclusion Criteria:~* You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder.~* You have taken a drug within the last 30 days that has not been approved for use by governmental authorities.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Breastfeeding women with IBD or healthy breastfeeding women in the first 4-month postpartum period~Exclusion Criteria:~* unable to communicate in English~* Present illness of chronic inflammatory conditions (except IBD)~* Mastitis~* Present acute or chronic infection~* use of a different anti-TNFα drug within the last 2 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Women with IBD (Type: None): This group is composed of breastfeeding women aged over 18 years and in their first 4-month postpartum period, who are diagnosed with Crohn's disease or Ulcerative Colitis.
- Healthy breastfeeding women (Type: None): This group is composed of healthy breastfeeding women aged over 18 years and in their first 4-month postpartum period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 10 to 70 years~* Diagnosis of acute AIH according to Alvarez score~* normal range of TPMT activity~* normal ACTH test~* negative pregnancy test at screening for females of childbearing potential~* written informed consent~Exclusion Criteria:~* presence of Hepatitis A, B, C, E or G virus infection~* liver cirrhosis or clinical signs of portal hypertension~* PBC~* PSC~* history of hypersensitivity to the study medication

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- budesonide (Type: EXPERIMENTAL): 3mg capsules 3x/day for 6 months
- prednisone (Type: ACTIVE_COMPARATOR): 5mg tablet, 40mg starting dose titrated to 10mg over 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Use of a standard-of-care statin at a stable dose, or intolerance of statins, without use of other lipid modifying therapies~* Fasting LDL cholesterol 90-250 mg/dL on the statin regimen above~And at least one of the following:~* Coronary heart disease (CHD) with a history of myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft surgery (CABG), or prior coronary angiography demonstrating coronary atherosclerosis~* A CHD risk equivalent condition, including diabetes mellitus (type 1 or 2), chronic kidney disease, prior stroke, carotid disease, peripheral arterial disease, or abdominal aortic aneurism~* \>/=2 CHD risk factors (age \>/= 45 years for men or \>/= 55 years for women; smoking; hypertension; low HDL cholesterol; family history of premature CHD) and a high risk of a CV event based on risk estimation systems~Exclusion Criteria:~* Severe congestive heart failure (NYHA Class III-IV) or left ventricular ejection fraction \</= 35%~* Recent (within 3 months) MI, unstable angina, stroke, transient ischemic attack, CABG, PCI, hospital admission for heart failure, major surgery, uncontrolled cardiac arrhythmia (other than atrial fibrillation or flutter), or initiation of renal replacement therapy (dialysis)~* Fasting serum triglyceride level \>/= 400 mg/dL~* Homozygous familial hypercholesterolemia~* Poorly controlled diabetes mellitus, hypertension or thyroid disease~* Liver or muscle disease, including abnormal test results at screening~* Pregnant or lactating~The above list is not intended to contain all factors relevant to a patient's eligibility for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None
- E (Type: EXPERIMENTAL): None
- F (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Each participant must meet all of the following inclusion criteria to be enrolled in the study:~1. Male or female participants 18 years or older, with relapsed or refractory classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen~2. Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:~   * Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy~  * Progressive disease during frontline multiagent chemotherapy~  * Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments~3. Bidimensional measurable disease~4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1~5. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception at the same time, or agree to practice true abstinence.~6. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence.~7. Clinical laboratory values as specified in the study protocol.~Exclusion Criteria:~Participants who meet any of the following exclusion criteria are not to be enrolled in the study:~1. Previous treatment with brentuximab vedotin~2. Previously received an autologous stem cell transplantation (ASCT) or alloSCT~3. Known cerebral/meningeal disease, including signs or symptoms suggestive of progressive multifocal leukoencephalopathy (PML), or any history of PML.~4. Female participants who are lactating and breastfeeding or pregnant.~5. Known human immunodeficiency virus (HIV).~6. Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection.~7. Grade 2 or higher peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin 1.8 mg/kg (Type: EXPERIMENTAL): Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of Pulmonary Arterial Hypertension (PAH) due to the following:~  a. idiopathic or heritable PAH b. PAH associated with: i. connective tissue disease (e.g., limited scleroderma, diffuse scleroderma, mixed connective tissue disease, systemic lupus erythematosus, or overlap syndrome) ii. drugs or toxins iii. Human Immunodeficiency Virus (HIV) infection iv. congenital heart defects repaired greater than 1 year prior to screening (i.e., atrial septal defects, ventricular septal defects, and patent ductus arteriosus) NB: subjects with portopulmonary hypertension and pulmonary veno-occlusive disease are NOT eligible for the study~* Subject must have a current diagnosis of being in World Health Organisation (WHO) Functional Class II or III.~* Subject must meet all of the following haemodynamic criteria by means of a right heart catheterization prior to screening:~  i. mPAP of ≥25 mmHg ii. PVR ≥ 300 dynes/sec/cm5 iii. PCWP or LVEDP of ≤12 mmHg if PVR ≥300 to \<500 dyne/sec/cm5 , or PCWP/LVEDP ≤ 15 mmHg if PVR ≥500 dynes/sec/cm5~* Subject must walk a distance of ≥125m and ≤500m at the screening visit~Exclusion Criteria:~* Subject received previous PAH therapy (phosphodiesterase type 5 inhibitor (PDE5i), endothelin receptor antagonist (ERA), chronic prostanoid\*) within 4 weeks prior to the screening visit (\*Chronic prostanoid use is considered \>7 days of treatment)~* Subject received ERA treatment (e.g., bosentan or sitaxentan) or PDE5i treatment (e.g. Sildenafil) at any time AND discontinued due to tolerance issues other than those associated with liver function abnormalities~* Subjects who have previously discontinued ambrisentan or tadalafil in either another clinical study or commercial product (Volibris/Letairis or Adcirca) for safety or tolerability reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Combination ambrisentan + tadalafil (Type: ACTIVE_COMPARATOR): ambrisentan + tadalafil
- Monotherapy ambrisentan (Type: ACTIVE_COMPARATOR): ambrisentan
- Monotherapy tadalafil (Type: ACTIVE_COMPARATOR): tadalafil

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete